deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02178241

Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery

Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder

Sponsor: National Cancer Institute (NCI)

Conditions Metastatic Ureter Carcinoma Metastatic Urethral Carcinoma Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 Stage III Ureter Cancer AJCC v7 Stage III Urethral Cancer AJCC v7 Stage IV Bladder Urothelial Carcinoma AJCC v7 Stage IV Ureter Cancer AJCC v7 Stage IV Urethral Cancer AJCC v7 Ureter Urothelial Carcinoma Urethral Urothelial Carcinoma
Interventions Eribulin Mesylate Gemcitabine Hydrochloride
Updated 21 times since 2017 Last updated: Nov 20, 2019 Started: Dec 11, 2014 Primary completion: Mar 18, 2019 Completion: Jul 11, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Ureter Carcinoma and Metastatic Urethral Carcinoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 21 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Dec 2017 · 6 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Oct 2018 · 3 months · monthly snapshot~Oct 2018 – ~Mar 2019 · 5 months · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Jan 2020 · 5 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

▶ Show 16 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2

  2. Jan 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. Aug 2019 — Jan 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Jul 2019 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  5. May 2019 — Jul 2019 [monthly]

    Active Not Recruiting PHASE2

  6. Apr 2019 — May 2019 [monthly]

    Active Not Recruiting PHASE2

  7. Mar 2019 — Apr 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Oct 2018 — Mar 2019 [monthly]

    Active Not Recruiting PHASE2

  9. Jul 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE2

  11. Feb 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  12. Dec 2017 — Feb 2018 [monthly]

    Active Not Recruiting PHASE2

  13. Jun 2017 — Dec 2017 [monthly]

    Active Not Recruiting PHASE2

  14. May 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  15. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Buffalo, United States , Chicago, United States , Cleveland, United States , Columbus, United States , Duarte, United States , Houston, United States , Los Angeles, United States , New Lenox, United States , Pasadena, United States and 6 more locations